The TGA has approved Ryeqo - the first new treatment for endometriosis in Australia in 13 years. 

Ryeqo, a combination of relugolix, estradiol, and norethisterone, offers a novel approach to managing the debilitating symptoms of endometriosis, which impacts 14 per cent of women of reproductive age.

Endometriosis, characterised by the presence of tissue similar to the uterine lining growing outside the uterus, causes chronic pain, inflammation, and can severely affect quality of life and fertility. 

The condition is notoriously challenging to diagnose and treat, often requiring surgery or ongoing medication. 

Ryeqo aims to alleviate these symptoms by regulating hormone levels in the body, reducing oestrogen and progesterone levels while compensating for oestrogen loss to prevent side effects like hot flushes and bone density loss.

Despite its availability in Australia since 2022 for uterine fibroids, Ryeqo's recent approval specifically targets endometriosis treatment. 

However, the drug's cost has been a significant barrier for many, with users facing charges up to $135 for a month's supply pending a decision by the Pharmaceutical Benefits Advisory Committee (PBAC) on its subsidisation.

Pharmaceutical company Gedeon Richter has applied for the drug to be subsidised under the PBS, pending a decision by the Pharmaceutical Benefits Advisory Committee – to be announced later this month. Details from the company are accessible in PDF form, here.

Medical professionals and organisations have welcomed Ryeqo's approval, highlighting it as a critical addition to the limited options available for endometriosis management.

Experts have noted the importance of having a non-contraceptive endometriosis treatment option, which could be particularly beneficial for women from diverse cultural and linguistic backgrounds.